Financials Galenica AG OTC Markets

Equities

GALNF

CH0360674466

Pharmaceuticals

Market Closed - OTC Markets 09:30:04 2022-11-23 am EST 5-day change 1st Jan Change
75.25 USD -.--% Intraday chart for Galenica AG -.--% -.--%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,943 2,911 3,393 3,750 3,624 3,670 - -
Enterprise Value (EV) 1 3,269 3,492 3,901 4,343 4,283 4,204 4,175 4,199
P/E ratio 23.7 x 17 x 20.3 x 22.8 x 22 x 21.7 x 19.9 x 18.5 x
Yield 3.01% 3.05% 3.06% 2.91% 3.02% 3.07% 3.21% 2.58%
Capitalization / Revenue 0.89 x 0.84 x 0.88 x 0.93 x 0.97 x 0.94 x 0.9 x 0.87 x
EV / Revenue 0.99 x 1 x 1.02 x 1.08 x 1.14 x 1.07 x 1.02 x 0.99 x
EV / EBITDA 12.6 x 11.3 x 14.9 x 17.4 x 17.7 x 13.7 x 12.8 x 12.3 x
EV / FCF 16.6 x 18.6 x 13.4 x 22.2 x 28.7 x 21.2 x 19.2 x 17.6 x
FCF Yield 6.02% 5.38% 7.46% 4.51% 3.49% 4.71% 5.2% 5.68%
Price to Book 2.97 x 2.78 x 2.77 x 3.02 x 2.46 x 2.39 x 2.28 x 2.19 x
Nbr of stocks (in thousands) 49,177 49,339 49,499 49,638 49,816 49,832 - -
Reference price 2 59.85 59.00 68.55 75.55 72.75 73.65 73.65 73.65
Announcement Date 3/9/20 3/9/21 3/8/22 3/29/23 3/12/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,301 3,480 3,835 4,014 3,746 3,919 4,075 4,230
EBITDA 1 260.3 309.5 262.3 249.9 242.2 307.6 325.9 340.1
EBIT 1 166.9 168.6 213.1 200.8 191.3 212.5 227.4 245.5
Operating Margin 5.06% 4.85% 5.56% 5% 5.11% 5.42% 5.58% 5.8%
Earnings before Tax (EBT) 1 163.4 208.6 203 199.6 194.9 202.4 213.5 230.3
Net income 1 125 172.2 167.7 165.1 285.4 173.9 183.3 190.6
Net margin 3.79% 4.95% 4.37% 4.11% 7.62% 4.44% 4.5% 4.51%
EPS 2 2.530 3.480 3.380 3.320 3.310 3.396 3.701 3.989
Free Cash Flow 1 196.8 187.9 291.2 195.8 149.3 198.2 217.1 238.5
FCF margin 5.96% 5.4% 7.59% 4.88% 3.99% 5.06% 5.33% 5.64%
FCF Conversion (EBITDA) 75.62% 60.7% 110.99% 78.36% 61.66% 64.42% 66.62% 70.12%
FCF Conversion (Net income) 157.49% 109.07% 173.64% 118.58% 52.33% 113.99% 118.43% 125.09%
Dividend per Share 2 1.800 1.800 2.100 2.200 2.200 2.264 2.367 1.903
Announcement Date 3/9/20 3/9/21 3/8/22 3/29/23 3/12/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1
Net sales 1 1,690 1,789 - 1,978 1,960 2,054 1,851
EBITDA 1 105.3 180.2 - - 152.6 126.2 143.9
EBIT 1 83.58 - 101.4 111.7 100 100.8 92.52
Operating Margin 4.94% - - 5.65% 5.1% 4.91% 5%
Earnings before Tax (EBT) - - - - - - -
Net income 1 66.17 106.1 - 88.38 82.91 82.22 187
Net margin 3.91% 5.93% - 4.47% 4.23% 4% 10.1%
EPS 2 1.340 2.140 - 1.780 1.670 1.650 1.490
Dividend per Share - - - - - - -
Announcement Date 8/4/20 3/9/21 - 3/8/22 8/9/22 3/29/23 8/8/23
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 326 581 508 593 658 534 505 529
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.253 x 1.877 x 1.935 x 2.371 x 2.718 x 1.735 x 1.549 x 1.556 x
Free Cash Flow 1 197 188 291 196 149 198 217 238
ROE (net income / shareholders' equity) 14% 16.9% 14.7% 13.4% 21% 11.5% 11.8% 12.2%
ROA (Net income/ Total Assets) 6.6% 7.71% 6.95% 6.38% 10.2% 5.61% 5.84% 6.13%
Assets 1 1,895 2,234 2,412 2,589 2,802 3,101 3,139 3,112
Book Value Per Share 2 20.20 21.20 24.80 25.00 29.50 30.80 32.30 33.60
Cash Flow per Share 2 5.070 4.530 6.710 4.760 4.520 5.010 5.850 5.630
Capex 1 53.6 55.1 41.9 41.1 76.4 110 110 110
Capex / Sales 1.62% 1.58% 1.09% 1.02% 2.04% 2.81% 2.71% 2.6%
Announcement Date 3/9/20 3/9/21 3/8/22 3/29/23 3/12/24 - - -
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
73.65 CHF
Average target price
77 CHF
Spread / Average Target
+4.55%
Consensus